FDA Approves RISPERIDONE — Par Health USA, LLC

Par Health USA, LLC announced the approval of its Abbreviated New Drug Application for Risperidone on April 30, 2009, which is expected to drive immediate competition against the branded market and expand generic accessibility for the antipsychotic. The manufacturing and marketing of this oral drug form could be a significant revenue driver for the emerging generic manufacturer, enhancing its position in the psychiatric pharmaceuticals segment.